跳转至内容
Merck
所有图片(1)

Key Documents

G004366

HPLC Analysis of Verapamil and Metabolites in Rat Plasma on Ascentis® Express C18 after Phospholipid Removal using HybridSPE®-Phospholipid

application for SPE, application for LC-MS

登录查看公司和协议定价


About This Item

技術

LC/MS: suitable
solid phase extraction (SPE): suitable

測試參數

SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample preparation: SPE (Solid Phase Extraction)
column: Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U)
sample/matrix: Rat plasma spiked with verapamil and metabolites at 10 ng/mL
mobile phase: [A] water; [B] acetonitrile, pH 2.55 adjust with formic acid (30:70, A:B)
flow rate: 0.6 mL/min
column temp.: 35 °C
detector: TOF/MS
injection: 1 μL
sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile
elution: apply vacuum

適合性

application for LC-MS
application for SPE

應用

clinical

法律資訊

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门